Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Similar Posts
Gen Z, millennials are ‘house hacking’ to become homeowners. How the strategy can help
Gen Zers and millennials are using “house hacking” as a way to secure homeownership in a tough market. Here’s how the strategy works. Post Views: 51
Helium Evolution GAAP EPS of -C$0.01
Post Content Post Views: 60
BMO Floating Rate High Yield ETF declares CAD 0.105 dividend
Post Content Post Views: 48
ATRenew Non-GAAP EPS of $0.04, revenue of $446.4M; initiates Q4 outlook
Post Content Post Views: 73
US existing home sales slump to more than 13-year low, prices accelerate
Post Content Post Views: 55
BRAG, GMGI among major communication services gainers; ANGH, SLE among losers
Post Content Post Views: 63